|Day's Range||4.90 - 5.05|
|52 Week Range||3.60 - 7.57|
|PE Ratio (TTM)||-8.15|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||11.33|
Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, today announced that Michal Preminger, PhD, MBA, Executive Director at Harvard University Office of Technology Development's Harvard Medical School site, has been appointed a Director of Compugen by the Company's Board of Directors. Dr. Preminger brings to Compugen broad managerial and business experience focused on the pharma and biotech industries.
HOLON, Israel, May 23, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, today announced that Dr. Anat Cohen-Dayag, President and Chief Executive Officer, will present ...
Compugen Ltd. (CGEN) shares rose over 10% in the last trading session.